Pharmacotherapy in personality disorders;Pharmakotherapie bei persönlichkeitsstörungen

Fortschritte der Neurologie Psychiatrie

Volumn 73, Issue 5, 2005, Pages 259-267

  Wedekind, Dirk ^a   Bandelow, B ^a   Ruther E ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BROFAROMINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; HALOPERIDOL; HYPNOTIC AGENT; IMIPRAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; OPIATE ANTAGONIST; OXAZEPAM; PHENELZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TIOTIXENE; TIZANIDINE; TRANYLCYPROMINE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; VALPROIC ACID; VENLAFAXINE;

ALGORITHM; ARTICLE; BIPOLAR DISORDER; BORDERLINE STATE; COMORBIDITY; EMOTIONAL DISORDER; HISTRIONIC PERSONALITY DISORDER; HUMAN; LONG TERM CARE; PASSIVE AGGRESSIVE PERSONALITY DISORDER; PERSONALITY DISORDER; PSYCHOPATHY; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; SCHIZOTYPAL PERSONALITY DISORDER; SOCIAL PHOBIA;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; LITHIUM; NALTREXONE; NARCOTIC ANTAGONISTS; PERSONALITY DISORDERS; PSYCHOTROPIC DRUGS;

EID: 19444363532     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830107     Document Type: Article

References (77)

1. Soloff PH. Pharmacotherapy of borderline disorders. Compr Psychiatry 1981; 22: 535-543
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association, 1994
3. Zimmermann M, Mattia JI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry 1999; 40: 245-252
4. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1997; 52: 13-19
5. Androlunis PA, Gluech BC, Stroebel CF et al. Borderline personality disorder subcategories, J Nerv Ment Disord 1982; 170: 670-679
6. Stein G. Drug treatment of personality disorders. Br J Psychiatry 1992; 161: 167-184
7. Cloninger CR, Svarik DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry 1993; 50: 975-990
8. Soloff PH. Special feature: Psychobiologic perspectives on treatment of personality disorders. J Person Disord 1997; 11 (4): 336-344
9. Schmahl C, Bohus M. Symptomorientierte Pharmakotherapie bei Borderline-Persönlichkeitsstörung. Fortschr Neurol Psychiat 2001; 69: 310-321
10. Hirschfeld RMA. Pharmacotherapy of borderline personality disorder. J Clin Psychiatry 1997; 58 (Suppl. 14): 48-52
11. Soloff PH, George A, Nathan RS, Schut PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders: A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43: 691-697
12. Soloff PH, George A, Nathan S. Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. J Clin Psychopharmacol 1989; 9: 238-246
13. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50(5): 377-385
14. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazin and tranylcypromine. Arch Gen Psychiatry 1988; 45: 111-119
15. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43: 680-686
16. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect Disord 1982; 4: 291-298
17. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: A preliminary study. Compr Psychiatry 1993; 34: 402-405
18. Benedetti F, Sforzini L, Colombo C et al. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59: 103-107
19. Chengappa KN, Baker RW, Sirri C. The succesful use of clozapine in ameliorating severe self mutilation in a patient with borderline personality disorder. J Pers Disord 1995; 9: 76-82
20. Szigethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psychopharmcol 1997; 17: 326-327
21. Rocca P, Marchiario L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63 (3): 241-244
22. Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, Silverman J, Siever LJ. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003; 64 (6): 628-634
23. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapin safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46: 1429-1435
24. Zullino DF, Quinche P, Haflinger T, Stigler M. Olanzapin improves social dysfunction in cluster B personality disorder. Hum Psychopharmacol 2002; 17 (5): 247-251
25. Hilger E, Barnas C, Kasper S. Quetiapin in the treatment of borderline personality disorder. World J Biol Psychiatry 2003; 4 (1): 42-44
26. Walker C, Thomas J, Allen TS. Treating impulsivity, irritability, and aggression of antisocial personality disorder with quetiapine. Int J Offender Ther Comp Criminol 2003; 47 (5): 556-567
27. Liebowitz MR, Quitkin FM, Stewart JW et al. Antidepressant specificy in atypical depression. Arch Gen Psychiatry 1988; 45: 129-137
28. Parsons B, Quitkin FM, McGrath PJ et al. Phenelzine, imipramine and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989; 25: 524-534
29. Baer L, Jenike MA, Ricciardy JN et al. Standardized assessment of personality disorders in obsessive compulsive disorder. Arch Gen Psychiatry 1990; 47: 826-830
30. Insel TR, Zohar J. Psychopharmacologic approaches to obsessive compulsive disorder. In: Meltzer HY (Hrsg.). Psychopharmacology: The third generation in progress. New York: Raven Press, 1987: 1205-1210
31. Akiskal HS, Rosenthal TL, Haykal RF et al. Clinical and sleep EEC findings seperating "subaffective dysthymias" from "character spectrum disorders". Arch Gen Psychiatry 1980; 37: 777-793
32. Shawcross CR, Tyrer P. The influence of personality on response to monoamine oxidase inhibitors and tricyclic antidepressants. J Psychiat Res 1985; 19: 557-562
33. Black DW, Bell S, Hulbert J et al. The importance of Axis-II in patients with major depression. J Affect Disord 1988; 14: 115-122
34. Vliet I van, Boer JA den, Westenberg HGM. Psychopharmacological treatment of social phobia-a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994; 115: 128-134
35. Fahlen T, Nillson HL, Borgm K et al. Social phobia: The clinical efficacy and tolerability of the monoamine oxydase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand 1995; 92: 351-358
36. Versiani M, Nardi AE, Mundim FD et al. Pharmacotherapy of social phobia - a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353-360
37. Markowitz PJ, Calabrese JR, Schulz SC et al. Fluoxetine treatment of borderline and schizotypal personality disorder. Am J Psychiatry 1991 ; 148: 1064-1067
38. Salzman S, Wolfson AN, Schatzberg A et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15: 23-29
39. Cocarro EF, Astill JF, Herbert JL, Schut AG. Fluoxetine treatment of impulsive aggression in DSM III-R personality disorder patients. J Clin Pharmacol 1990; 105: 373-375
40. Cornelius JR, Soloff PH, Perel JM, Ulrich R. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26: 149-152
41. Mulder RT, Joyce PR, Luty SE. The relationship of personality disorders to treatment outcome in depressed outpatients. J Clin Psychiatry 2003; 64 (3): 259-264
42. Kavoussi RJ, Liu J, Cocarro EF. An open trial of sertraline in personality-disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55: 137-141
43. Markowitz PJ. Pharmacotherapy of impulsivity, aggression and related disorders. In: Stein D, Hollander E (Hrsg.). Impulsive aggression and disorders of Impulse control. Sussex, England: J Wiley, 1995: 263-287
44. Katzelnick DJ, Kobak KA, Greist JH et al. Sertraline for social phobia: Placebo-controlled crossover study. Am J Psychiatry 1995; 152: 1368-1371
45. Vliet I van, Boer JA den, Westenber HGM. Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur J Neuropychopharmacol 1992; 2: 21-29
46. Rinne T, Brink W van den, Wouters L, Dyck R van. SSRI treatment of borderline personality disorder, a randomized, placebo-controlled trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159 (12): 2048-2054
47. Reist C, Nakamura K, Sagart E, Sokolski KN, Fujimto KA. Impulsive aggressive behaviour: open-label treatment with citalopram. J Clin Psychiatry 2003; 64 (1): 81-85
48. Markowitz PJ, Wagner SC. Venlafaxin in the treatment of borderline personality disorder. Psychopharmacol Bull 1995; 31: 773-777
49. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioural dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143: 519-522
50. De La Fuente JM, Lotstra F. A trial of carbamazepin in borderline personality disorder. Eur Neuropsychopharmacol 1994; 4: 479-486
51. Stein DJ, Simeon D, Frenkel M et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995; 56: 506-506
52. Wilcox JA. Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 1995; 7: 33-37
53. Cocarro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behaviour in personality-disordered subject. Arch Gen Psychiatry 1997; 54: 1081-1088
54. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozna P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003; 28 (6): 1186-1197
55. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63 (5): 442-446
56. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to border-line personality: an open case series without concurrent DSM IV major mood disorder. J Affect Disord 1998; 52 (3): 333-343
57. Rizvi ST. Lamotrigine and borderline personality disorder. J Child Adolescent Psychopharmacol 2002; 12 (4): 365-366
58. Sheard MH. Effect of lithium on human aggression. Nature 1971; 230: 113-114
59. Rifkin A, Quitkin F, Carrillo C et al. Lithium carbonate in emotionally unstable character disorders. Arch Gen Psychiatry 1972; 27: 519-523
60. Tupin JP, Smith DB, Clanon TL et al. The long-term use of lithium in aggressive prisoners. Compreh Psychiatry 1973; 14: 311-317
61. Sheard MH, Marini JL, Bridges CI et al. The effect of lithium on unipolar aggressive behaviour in man. Am J Psychiatry 1976; 133: 1409-1413
62. Links P. Lithium therapy for borderline patients. J Pers Disord 1990; 4: 173-181
63. Lion JR. Benzodiazepines in the treatment of aggressive patients. J Clin Psychiatry 1979; 40: 70-71
64. Eichelmann B. Toward a rational pharmacotherapy for aggressive and violent behaviour. Hosp Comm Psychiatry 1988; 39: 31-39
65. Faltus FJ. The use of alprazolam in the treatment of three patients with borderline personality disorder. Am J Psychiatry 1984; 141: 802-803
66. Freinhar JP, Alvarez WA. Clonazepam: A novel therapeutic ajunct. Int J Psychiatry Med 1986; 15 (4): 321-328
67. Bick PA, Hannah AL. Intramuscular lorazepam to restrain violent patients. Lancet 1986; 1: 206-206
68. Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985; 142: 98-100
69. Reich J, Noyes R, Troughton ED. Alprazolam treatment of avoidant personality traits in social phobic patients. J Clin Psychiatry 1988; 50: 91-95
70. Roth AS, Ostroff RB, Huffman RE. Naltrexone as a treatment for repetitive self-injurious behaviour: an open label trial. J Clin Psychiatry 1996; 57: 233-293
71. Sonne S, Rubey R, Brady K et al. Naltrexone treatment of self-injurious thoughts and behaviours. J Nerv Ment Dis 1996; 184: 192-195
72. Mc Gee MD. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. J Clin Psychiatry 1997; 58(1): 32-33
73. Bohus MJ, Landwehrmeyer BG, Stiglmeyr CE, Limberger MF, Bohme R, Schmahl CG. Naltrexon in the treatment of dissociative symptoms in patient with borderline personality disorder: an open-label trial. J Clin Psychiatry 1999; 60 (9): 598-603
74. Sofoff PH. Algorithms for pharmacological treatment of personality dimensions: Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioural dysregulation. Bull Menning Clin 1998; 62 (2): 195-214
75. American Psychiatric Association. Practical guidelines for the treatment of borderline personality disorder. Am J Psychiatry 2001; 158 (Suppl. 10): 1-44
76. Zanarini MC. Update on pharmacotherapy of borderline personality disorder. Curr Psychiatry Rep 2004; 6 (1): 66-70
77. Newton-Howes G, Tyrer P. Pharmacotherapy for personality disorders. Expert Opin Pharmacother 2003; 4 (10): 1643-1649